share_log

10-Q: Quarterly report

10-Q: Quarterly report

10-Q：季度报表
美股sec公告 ·  05/15 16:19
Moomoo AI 已提取核心信息
TC BioPharm, a clinical-stage biopharmaceutical company, reported its financial performance for the quarter ended March 31, 2024. The company experienced a net loss of £3.3 million, a significant increase from the £0.6 million net loss in the same period the previous year. This was attributed to a decrease in research and development expenses, which dropped by 33% to £1.3 million, and a decrease in administrative expenses by 4% to £2.1 million. The company's cash and cash equivalents stood at £1.0 million as of March 31, 2024. TC BioPharm's business development focused on advancing its pipeline of unmodified allogeneic GD-T therapies and next-generation GD CAR-T treatments. The company's future plans include continuing its clinical trials, expanding its manufacturing capabilities, and potentially commercializing its product candidates. However, the report indicates substantial doubt about the company's ability to continue as a going concern, with current cash reserves expected to fund operations only into July 2024. Additional funding will be necessary to sustain operations beyond that point.
TC BioPharm, a clinical-stage biopharmaceutical company, reported its financial performance for the quarter ended March 31, 2024. The company experienced a net loss of £3.3 million, a significant increase from the £0.6 million net loss in the same period the previous year. This was attributed to a decrease in research and development expenses, which dropped by 33% to £1.3 million, and a decrease in administrative expenses by 4% to £2.1 million. The company's cash and cash equivalents stood at £1.0 million as of March 31, 2024. TC BioPharm's business development focused on advancing its pipeline of unmodified allogeneic GD-T therapies and next-generation GD CAR-T treatments. The company's future plans include continuing its clinical trials, expanding its manufacturing capabilities, and potentially commercializing its product candidates. However, the report indicates substantial doubt about the company's ability to continue as a going concern, with current cash reserves expected to fund operations only into July 2024. Additional funding will be necessary to sustain operations beyond that point.
临床阶段的生物制药公司TC BioPharm公布了截至2024年3月31日的季度财务业绩。该公司的净亏损为330万英镑，较去年同期的60万英镑净亏损大幅增加。这归因于研发费用减少，下降了33％，至130万英镑，管理费用减少了4％，至210万英镑。截至2024年3月31日，该公司的现金和现金等价物为100万英镑。TC BioPharm的业务发展侧重于推进其未改良的异基因GD-T疗法和下一代GD CAR-T疗法的产品线。该公司的未来计划包括继续进行临床试验，扩大其制造能力，并可能将其候选产品商业化。但是，该报告显示，人们对该公司继续经营的能力存在严重怀疑，目前的现金储备预计要到2024年7月才能为运营提供资金。在此之后，将需要额外的资金来维持业务。
临床阶段的生物制药公司TC BioPharm公布了截至2024年3月31日的季度财务业绩。该公司的净亏损为330万英镑，较去年同期的60万英镑净亏损大幅增加。这归因于研发费用减少，下降了33％，至130万英镑，管理费用减少了4％，至210万英镑。截至2024年3月31日，该公司的现金和现金等价物为100万英镑。TC BioPharm的业务发展侧重于推进其未改良的异基因GD-T疗法和下一代GD CAR-T疗法的产品线。该公司的未来计划包括继续进行临床试验，扩大其制造能力，并可能将其候选产品商业化。但是，该报告显示，人们对该公司继续经营的能力存在严重怀疑，目前的现金储备预计要到2024年7月才能为运营提供资金。在此之后，将需要额外的资金来维持业务。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息